{
  "success": true,
  "pagesUsed": [
    0,
    1,
    2,
    3,
    4,
    6,
    7,
    20,
    25,
    26,
    34,
    41,
    45,
    47,
    48,
    49,
    50,
    52,
    54
  ],
  "modelUsed": "gemini-2.5-pro",
  "confidence": 1.0,
  "documentStructure": {
    "documentContentReferences": [
      {
        "id": "ref_1",
        "name": "Reference to SoA Table from Amendment Summary",
        "instanceType": "DocumentContentReference",
        "sectionNumber": "1.3",
        "sectionTitle": "Schedule of Activities (SoA), Table 1",
        "description": "Reference from the 'PROTOCOL AMENDMENT SUMMARY OF CHANGES TABLE' to the Schedule of Activities table regarding a footnote addition."
      },
      {
        "id": "ref_2",
        "name": "Reference to Study Assessments from Amendment Summary",
        "instanceType": "DocumentContentReference",
        "sectionNumber": "8",
        "sectionTitle": "Study Assessments and Procedures",
        "description": "Reference from the 'PROTOCOL AMENDMENT SUMMARY OF CHANGES TABLE' to Section 8 for details on procedures at screening-only sites."
      },
      {
        "id": "ref_3",
        "name": "Reference to COVID-19 Vaccine Risk Assessment",
        "instanceType": "DocumentContentReference",
        "sectionNumber": "10.5",
        "sectionTitle": "COVID-19 Vaccine Risk Assessment",
        "description": "Reference from Section 2.3.1.1 to the section on potential risks and mitigation measures due to the COVID-19 vaccine."
      },
      {
        "id": "ref_4",
        "name": "Reference to Dose Modification",
        "instanceType": "DocumentContentReference",
        "sectionNumber": "6.6",
        "sectionTitle": "Dose Modification",
        "description": "Multiple references from Table 3 to Section 6.6 for dose modification or discontinuation strategies."
      },
      {
        "id": "ref_5",
        "name": "Reference to Investigator's Brochure",
        "instanceType": "DocumentContentReference",
        "sectionNumber": "N/A",
        "sectionTitle": "Investigator's Brochure",
        "description": "Multiple references to the Investigator's Brochure (IB) for supporting data on potential risks."
      },
      {
        "id": "ref_6",
        "name": "Reference to Adaptive Protocol Features Table",
        "instanceType": "DocumentContentReference",
        "sectionNumber": "Table 4",
        "sectionTitle": "Adaptive Protocol Features",
        "description": "Reference from Section 4.1 to Table 4, which describes the study's adaptive features."
      },
      {
        "id": "ref_7",
        "name": "Reference to Dose Modification Criteria Table",
        "instanceType": "DocumentContentReference",
        "sectionNumber": "Table 7",
        "sectionTitle": "ALXN1840 Dose Modifications for Individual Participants",
        "description": "Reference from Table 4 to Table 7 for dose modification criteria."
      },
      {
        "id": "ref_8",
        "name": "Reference to Exclusion Criteria for Blood Donation",
        "instanceType": "DocumentContentReference",
        "sectionNumber": "5.2",
        "sectionTitle": "Exclusion Criteria",
        "description": "Reference from Table 5 (Lifestyle Considerations) to the exclusion criteria regarding blood donation."
      },
      {
        "id": "ref_9",
        "name": "Reference to Contraceptive Guidance",
        "instanceType": "DocumentContentReference",
        "sectionNumber": "10.4",
        "sectionTitle": "Contraceptive Guidance and Collection of Pregnancy Information",
        "description": "Reference from Table 5 (Lifestyle Considerations) to the section detailing appropriate contraceptive methods."
      },
      {
        "id": "ref_10",
        "name": "Reference to Inclusion Criteria for Contraception",
        "instanceType": "DocumentContentReference",
        "sectionNumber": "5.1",
        "sectionTitle": "Inclusion Criteria",
        "description": "Reference from Table 5 (Lifestyle Considerations) to the inclusion criteria regarding start times for contraceptives."
      },
      {
        "id": "ref_11",
        "name": "Reference to SoA for Discontinuation Procedures",
        "instanceType": "DocumentContentReference",
        "sectionNumber": "1.3",
        "sectionTitle": "Schedule of Activities (SoA)",
        "description": "Reference from Section 7.1 and 7.2 to the SoA for data collection procedures upon study intervention discontinuation."
      },
      {
        "id": "ref_12",
        "name": "Reference to Pregnancy Section",
        "instanceType": "DocumentContentReference",
        "sectionNumber": "8.2.6",
        "sectionTitle": "Pregnancy",
        "description": "Reference from Section 7.1 regarding discontinuation from study intervention due to pregnancy."
      },
      {
        "id": "ref_13",
        "name": "Reference to Discontinuation Section for QTc",
        "instanceType": "DocumentContentReference",
        "sectionNumber": "7",
        "sectionTitle": "Discontinuation of Study Intervention and Participant Discontinuation/Withdrawal",
        "description": "Reference from Section 8.2.3 to Section 7 for QTc withdrawal criteria."
      },
      {
        "id": "ref_14",
        "name": "Reference to Clinical Lab Tests Section",
        "instanceType": "DocumentContentReference",
        "sectionNumber": "10.2",
        "sectionTitle": "Clinical Laboratory Tests",
        "description": "Reference from Section 8.2.4 for the list of clinical laboratory tests to be performed."
      },
      {
        "id": "ref_15",
        "name": "Reference to AE/SAE Procedures",
        "instanceType": "DocumentContentReference",
        "sectionNumber": "10.3",
        "sectionTitle": "Adverse Events: Definitions and Procedures for Recording, Evaluating, Follow-up, and Reporting",
        "description": "Multiple references from Section 8.3 to Section 10.3 for procedures on detecting, recording, and following up on AEs and SAEs."
      },
      {
        "id": "ref_16",
        "name": "Reference to Lost to Follow-up Definition",
        "instanceType": "DocumentContentReference",
        "sectionNumber": "7.3",
        "sectionTitle": "Lost to Follow-up",
        "description": "Reference from Section 8.3.3 to the definition of 'lost to follow-up'."
      },
      {
        "id": "ref_17",
        "name": "Reference to Genetics Section",
        "instanceType": "DocumentContentReference",
        "sectionNumber": "8.7",
        "sectionTitle": "Genetics",
        "description": "Reference from Section 8.3.6 clarifying that biobanked samples will not be used for genetic testing."
      },
      {
        "id": "ref_18",
        "name": "Reference to SoA Table for PK/PD Sampling",
        "instanceType": "DocumentContentReference",
        "sectionNumber": "Table 1",
        "sectionTitle": "Schedule of Activities",
        "description": "Multiple references from Sections 8.5, 8.6, and 9.4.3 to the SoA table for sampling schedules."
      },
      {
        "id": "ref_19",
        "name": "Reference to Copper/Molybdenum Measurement Section",
        "instanceType": "DocumentContentReference",
        "sectionNumber": "8.1.1",
        "sectionTitle": "Copper and Molybdenum Balance Measurements",
        "description": "Reference from Sections 8.5 and 8.8 to details of copper and molybdenum measurements in various samples."
      },
      {
        "id": "ref_20",
        "name": "Reference to Pharmacodynamics Section",
        "instanceType": "DocumentContentReference",
        "sectionNumber": "8.6",
        "sectionTitle": "Pharmacodynamics",
        "description": "Reference from Section 8.8 to details of PD biomarker measurements."
      },
      {
        "id": "ref_21",
        "name": "Reference to Analysis Populations Table",
        "instanceType": "DocumentContentReference",
        "sectionNumber": "Table 8",
        "sectionTitle": "Populations for Analysis",
        "description": "Reference from Section 9.3 to the table defining the analysis populations."
      }
    ],
    "commentAnnotations": [
      {
        "id": "annot_1",
        "text": "Addition of text to the footnote to state that procedures specific to screening sites (only in the US) detailed in Section 8",
        "annotationType": "Clarification",
        "instanceType": "CommentAnnotation",
        "sourceSection": "PROTOCOL AMENDMENT SUMMARY OF CHANGES TABLE",
        "pageNumber": 3
      },
      {
        "id": "annot_2",
        "text": "To align the number of days with the mention of zinc discontinuation elsewhere in the protocol.",
        "annotationType": "Clarification",
        "instanceType": "CommentAnnotation",
        "sourceSection": "PROTOCOL AMENDMENT SUMMARY OF CHANGES TABLE",
        "pageNumber": 3
      },
      {
        "id": "annot_3",
        "text": "Abbreviations: ALT = alanine aminotransferase; AST = aspartate aminotransferase; IB = Investigatorâ€™s Brochure; PK = pharmacokinetics; WD = Wilson disease.",
        "annotationType": "Footnote",
        "instanceType": "CommentAnnotation",
        "sourceSection": "Table 3: Potential Risks and Mitigation Strategy",
        "pageNumber": 21
      },
      {
        "id": "annot_4",
        "text": "Abbreviations: CRF = case report form; CRU = clinical research unit; EOS = End of Study; SoA = Schedule of Activities.",
        "annotationType": "Footnote",
        "instanceType": "CommentAnnotation",
        "sourceSection": "Table 5: Participant Lifestyle Considerations",
        "pageNumber": 35
      },
      {
        "id": "annot_5",
        "text": "Abbreviations: ICF = informed consent form; PD = pharmacodynamic; PK = pharmacokinetic.",
        "annotationType": "Footnote",
        "instanceType": "CommentAnnotation",
        "sourceSection": "Table 8: Populations for Analysis",
        "pageNumber": 51
      },
      {
        "id": "annot_6",
        "text": "Note: total molybdenum and PUF molybdenum concentration-time profiles on Day 28 after the last 15 mg ALXN1840 dose will be extrapolated to Day 29 (0-24 hr) and subtracted from the observed Day 29 concentration-time profiles after the first 30 mg",
        "annotationType": "Note",
        "instanceType": "CommentAnnotation",
        "sourceSection": "9.4.4. Pharmacokinetic, Pharmacodynamic, and Biomarker Analyses",
        "pageNumber": 53
      }
    ],
    "studyDefinitionDocumentVersions": [
      {
        "id": "ver_1",
        "versionNumber": "3.1 (US)",
        "status": "Final",
        "instanceType": "StudyDefinitionDocumentVersion",
        "versionDate": "2022-03-18",
        "description": "Current protocol version as of document date.",
        "amendmentNumber": "Amendment 3.1 (US)"
      },
      {
        "id": "ver_2",
        "versionNumber": "3.0",
        "status": "Final",
        "instanceType": "StudyDefinitionDocumentVersion",
        "versionDate": "2021-08-31",
        "description": "Previous protocol version.",
        "amendmentNumber": "Amendment 3"
      },
      {
        "id": "ver_3",
        "versionNumber": "2.0",
        "status": "Final",
        "instanceType": "StudyDefinitionDocumentVersion",
        "versionDate": "2021-03-19",
        "description": "Previous protocol version.",
        "amendmentNumber": "Amendment 2"
      },
      {
        "id": "ver_4",
        "versionNumber": "1.0",
        "status": "Final",
        "instanceType": "StudyDefinitionDocumentVersion",
        "versionDate": "2020-08-18",
        "description": "Previous protocol version.",
        "amendmentNumber": "Amendment 1"
      },
      {
        "id": "ver_5",
        "versionNumber": "Original",
        "status": "Final",
        "instanceType": "StudyDefinitionDocumentVersion",
        "versionDate": "2020-05-12",
        "description": "Original protocol version."
      }
    ],
    "summary": {
      "referenceCount": 21,
      "annotationCount": 6,
      "versionCount": 5
    }
  }
}